Evidence map›Paper›PMID 39430298›Full record

ArticleCurrent opinion in biomedical engineering2024

Exploiting protein domain modularity to enable synthetic control of engineered cells.

Yusef Haikal, John Blazeck

Abstract read
In one paragraph

Article in Current opinion in biomedical engineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yusef HaikalSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta GA 303332, USA.
John BlazeckSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta GA 303332, USA.

Funding

Synthetic metabolism to armor and enhance a new class of cell therapiesDP2CA280622 · NCI · GEORGIA INSTITUTE OF TECHNOLOGY · PI BLAZECK, JOHN JAMES · 2022 to 2025
$2.3M
NCI NIH HHS DP2 CA280622
6 · The paper itself

Abstract

The ability to precisely control cellular function in response to external stimuli can enhance the function and safety of cell therapies. In this review, we will detail how the modularity of protein domains has been exploited for cellular control applications, specifically through design of multifunctional synthetic constructs and controllable split moieties. These advances, which build on techniques developed by biologists, protein chemists and drug developers, harness natural evolutionary tendencies of protein domain fusion and fission. In this light, we will highlight recent advances towards the development of novel immunoreceptors, base editors, and cytokines that have achieved intriguing therapeutic potential by taking advantage of well-known protein evolutionary phenomena and have helped cells learn new tricks via synthetic biology. In general, protein modularity, i.e., the relatively facile separation or (re)assembly of functional single protein domains or subdomains, is becoming an enabling phenomenon for cellular engineering by allowing enhanced control of phenotypic responses.

Indexed as

base editorscellular engineeringcytokinesprotein engineeringsynthetic receptors

Identifiers

PMID39430298
PMCPMC11486415

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.